Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 0.82 |
| ▸ | MMP1 | P03956 | 8/20 | 0.82 |
| ▸ | MMP9 | P14780 | 7/20 | 0.82 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.82 |
| ▸ | MMP3 | P08254 | 6/20 | 0.55 |
| ▸ | MMP2 | P08253 | 5/20 | 0.55 |
| ▸ | MMP14 | P50281 | 2/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927179 | 0.90 | MMP1 (1.00) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL1847769 | 0.90 | MMP1 (1.00) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL6928539 | 0.88 | MMP13 (0.71) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL6930725 | 0.87 | MMP1 (0.63) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL6929907 | 0.87 | MMP1 (0.77) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL6929682 | 0.86 | MMP9 (0.62) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL27512626 | 0.86 | MMP13 (0.75) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL6929323 | 0.85 | MMP13 (1.00) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL6928902 | 0.81 | MMP9 (0.69) | MMP13MMP1MMP9ADAM17MMP3 | |
| SCHEMBL6932328 | 0.81 | MMP1 (0.67) | MMP13MMP1MMP9ADAM17MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1784419-A | Streptococcus agalactiae antigens I and II | INTERCELL AG (AT) | 2006-06-07 | — | — | CN | claimed |
| EP-0970046-B1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2003-12-10 | — | — | EP | claimed |
| US-6172057-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-01-09 | — | — | US | claimed |
| CN-1252790-A | N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID CO (US) | 2000-05-10 | — | — | CN | claimed |
| CN-1784419-A | Streptococcus agalactiae antigens I and II | INTERCELL AG (AT) | 2006-06-07 | — | — | CN | disclosed |
| EP-0970046-B1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-12-12 | — | — | US | disclosed |
| US-6462073-B2 | METALLOPROTEASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-6444704-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-09-03 | — | — | US | disclosed |
| US-6342508-B1 | ENZYME INHIBITORS FOR PROTECTION OF CONNECTIVE TISSUES | AMERICAN CYANAMID COMPANY | 2002-01-29 | — | — | US | disclosed |
| US-6331563-B1 | LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE | WYETH HOLDINGS CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6288086-B1 | COMPOUNDS SUCH AS 1-METHYL-4-(4-BUTOXY-BENZENESULFONYL) -PIPERIDINE-4-CARBOXYLIC ACID HYDROXYAMIDE USED TO TREAT ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, ETC.; LOW MOLECULAR WEIGHT AND NON-PEPTIDAL | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| US-6197791-B1 | ANTIARTHRITIC AGENTS; WOUND HEALING AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6172057-B1 | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-01-09 | — | — | US | disclosed |
| EP-1054858-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-29 | — | — | EP | disclosed |
| EP-0973512-A1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1998037877-A1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | MMP13 17/4885MMP1 8/4885MMP9 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.